Abstract Center
Qualifications
The abstract submission is open to anyone interested in the research or development of cell and gene therapies or the treatment of patients with cell and gene therapies.
Abstract Type
Accepted abstracts will be presented as printed poster boards that will be on display throughout the meeting. Posters should be standard 36" x 48", although smaller sizes will be accepted.
Subject Categories
-
Adult Patient management from identification through treatment
-
Allogeneic CAR Ts and NKs
-
Anti-viral cell therapy
-
Apheresis for CAR-T
-
CAR T cell therapy for pediatric ALL patients
-
CAR T cells in special populations
-
Cell or Gene Therapy for Rare Diseases
-
Cellular raw material or final product biomarkers
-
Clinical Applications of CAR T Cells in Hematologic Malignancies
-
Clinical Applications of CAR T Cells in Solid Tumors
-
Ethical issues in Pediatric BMT
-
Financial implications for health systems
-
Gene Delivery and Editing for Better CARs
-
Gene edited Stem Cell Transplant for Sickle Cell Disease or Thalassemia
-
Gene Therapy for Hemophilia
-
Gene Therapy IND's and regulatory considerations
-
Globalization of CAR T-Cell Therapies
-
GVHD biomarkers
-
GVHD management - Adults
-
Logistics of cell collection
-
Management of pediatric patients receiving CAR T cell therapy for ALL
-
Managing side effects of CAR T-cell therapy – Adults
-
Minor donor collections and issues that arise: assent vs consent
-
New Targets and Technologies Allogeneic and Treg CAR Ts
-
Novel CAR Strategies
-
Overcoming Resistance
-
Processing apheresis cell product from collection to send off
-
Stem Cell Transplant for bone marrow failure
-
Stem Cell Transplant for Immunodeficiency
-
T Cell Fitness
-
The Role of Immunotherapies and Transplant in the Treatment of Multiple Myeloma
-
Toxicity Management
-
Unconventional CAR's
Submissions
Submission of an abstract constitutes a commitment to attend the meeting and address attendee questions if the abstract is accepted.
-
Abstract Deadline is 5pm ET on Wednesday, May 10, 2023
-
Abstracts must be submitted online HERE
-
Abstract submissions are limited to 2000 characters
-
Abstracts must be balanced and contain no commercial promotional content. Brand names of pharmaceuticals and trade names of medical devices cannot be used in the title or body of the abstract.
-
Abstracts must be proofread carefully to avoid errors before they are submitted. The University of Pennsylvania is not authorized to make changes to a submission. This includes typographical errors to the abstract title or text as well as additions or deletions of author names. Your abstract, if selected, will be published exactly as submitted.